Inhibitors of PAT1 do not alter the bioavailability of vigabatrin.

### Methods

Absorption was investigated in 78 Sprague Dawley rats after administration of vigabatrin, orally (0.3, 3.0 or 30mg/kg) or intravenously (1.0 mg/kg). Inhibition of PAT1 was investigated by co-administering proline/tryptophan (Pro/Trp) or sarcosine (Sar). Pharmacokinetic modelling was performed in NONMEM 7 with PsN, Pirana, Xpose and ggplot2 libraries for R.

### References

1. Perucca, E. Therapeutic drug monitoring 27.6 (2005): 714-717

### Acknowledgements

We highly appreciate the helpful support by PhD Trine Meldgaard Lund, University of Copenhagen, Denmark and PhD Kim Kristensen, Novo Nordisk A/S, Denmark

### Conclusion

• Inhibitors of PAT1 reduce the absorption rate of vigabatrin
• Inhibitors of PAT1 prolong the absorption delay of vigabatrin
• Inhibitors of PAT1 do not alter the bioavailability of vigabatrin

It is concluded that PAT1 is involved in intestinal absorption of vigabatrin in vivo.